Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | EEF2K | O00418 | 3/20 | 0.46 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.45 |
| ▸ | EEF2 | P13639 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | TSPO | P30536 | 2/20 | 0.36 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL399428 | 0.88 | KDM4E (0.56) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL399852 | 0.85 | KDM4E (0.58) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL13105851 | 0.85 | KDM4E (0.53) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL398453 | 0.83 | TSHR (0.56) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL398445 | 0.83 | KDM4E (0.74) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL399161 | 0.82 | ALDH1A1 (0.55) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL10148197 | 0.81 | TSPO (0.41) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL401113 | 0.81 | HPGD (0.61) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL398291 | 0.80 | KDM4E (0.57) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL399439 | 0.80 | KDM4E (0.57) | KDM4EALDH1A1HPGDTSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101604-B2 | Alpha carbolines and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20100311715-A1 | ALPHA CARBOLINES AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311715-A1 | ALPHA CARBOLINES AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311715-A1 | ALPHA CARBOLINES AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-7812018-B2 | inhibitors of I kappa B kinase ( IKK-2) 2-amino-9-methyl-9H-pyrido[2,3-b]indole-3-carboxamide, useful for treating inflammatory diseases and cancer | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7812018-B2 | inhibitors of I kappa B kinase ( IKK-2) 2-amino-9-methyl-9H-pyrido[2,3-b]indole-3-carboxamide, useful for treating inflammatory diseases and cancer | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7812018-B2 | inhibitors of I kappa B kinase ( IKK-2) 2-amino-9-methyl-9H-pyrido[2,3-b]indole-3-carboxamide, useful for treating inflammatory diseases and cancer | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20070207997-A1 | Alpha carbolines and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070207997-A1 | Alpha carbolines and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070207997-A1 | Alpha carbolines and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | disclosed |
| WO-2007097981-A2 | ALPHA CARBOLINES AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207997-A1 | Alpha carbolines and uses thereof | CHRM1, CNR1, CXCR1 | KDM4E 2021/4885ALDH1A1 416/4885HPGD 1661/4885 |
| US-20100311715-A1 | ALPHA CARBOLINES AND USES THEREOF | CHRM1, CNR1, CXCR1 | KDM4E 2021/4885ALDH1A1 416/4885HPGD 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.